Evidence Table 76. KQ2—Continuous data—Diastolic blood pressure (DBP)

| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ferraro 200922parallel | Unclear | ramipril | 10 | Omega-3 (EPA, DHA, or both).  | 15 | NR | Mean: 73.5Median SD: 20.3 | NR | NR |  | medium |
|  |  No treatment (aside from CVD drug) | 15 | Mean:76.7Median SD: 9.0 | NR |
| Meyer 200746parallel | Unclear | simvastatinstatin, 13 atorvastatin, 4 pravastatin, 2 cerivastatin and 2 ﬂuvastatin | 81 | Fish/marine oils.  | 13 | Supine in clinic | NR | NR | NR | Report states that no changes were noted in DBP across groups and results are not shown | medium |
|  | Fish/marine oils.  | 13 | NR | NR |
|  |  Placebo | 14 |
| Sutken 200663parallel | Low and/or Moderate | Gemfibrozil | 1200 | Vitamin E.  | 22 | NR | Mean: 84Median SD: SE: 4Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: |  | high |
|  |  No treatment (aside from CVD drug) | 23 | Mean:80Median SD: SE:6.4Lower: Upper: | Mean:Median:SD:P: |

| Evidence Table 76. KQ2—Continuous data—Diastolic blood pressure (DBP) (continued) |
| --- |
| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| Sutken 200663parallel | Low and/or Moderate | Gemfibrozil | 1200 | Vitamin E.  | 12 | NR | Mean: 80Median SD: SE:3.9Lower: Upper: | NR | NR  |  | high |
|  |  No treatment (aside from CVD drug) | 10 | Mean:81Median SD: SE:4.2Lower: Upper: | NR |
| Macan 200640parallel | Low and/or Moderate | Warfarin | NR | Garlic.  | 22 | NR | Mean: Median SD: SE:Lower: Upper: | Mean:-0.5% mean: Median:SD: 11.8P: | Mean:Median:SD:P: 0.829 |  | medium |
|  |  Placebo | 26 | Mean:Median SD: SE:Lower: Upper: | Mean:0.3Median:SD: 13.7P: |
| Barbagallo 19995parallel | Unclear | furosemide | 25 | Vitamin E.  | 12 | overnight fast, supine at rest, empty bladder | Mean:82 Median SD: 4SE:Lower: Upper: | Mean:-8% mean: Median:SD:P:<0.005 | Mean:Median:SD:P: | calculation of mean change from baseline questionably as it won’t be useable (SD cannot be inferred, I don’t think.). | medium |
|  |  No treatment (aside from CVD drug) | 12 | Mean:84Median SD: 6SE:Lower: Upper: | Mean:-9Median:SD:P:<0.005 |
| Howe 199430parallel | Unclear | Captopril | 61 | Fish/marine oils.  | 14 | NR | Mean: 77Median SD: SE:2Lower: Upper: | Mean:3.1% mean: Median:SD:P: | Mean:Median:SD:P: | outcomes in this study are reported as the average of three measurment during the treatment peiod. | medium |
|  |  Placebo | 14 | Mean:79Median SD: SE:2Lower: Upper: | Mean:2.3Median:SD:P: |
|  | Fish/marine oils.  | 14 | Mean:79Median SD: 2SE:Lower: Upper: | Mean:4.0Median:SD:1.1P: |
|  |  Placebo | 14 | Mean:77Median SD: 2SE:Lower: Upper: | Mean:4.4Median:SD:1.7P: |
| Paolisso 199257parallel | Unclear | hydrochlorthiazide | 25 | Magnesium.  | 9 | supine, fasted (12 h) and at rest for 30 minutes - measured over 60 minutes, mean of last 10 minutes of measurement included. | Mean: 95Median SD: SE:3Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P:<0.05 |  | medium |
|  |  Placebo | 9 | Mean:89Median SD: SE:5Lower: Upper: | Mean:Median:SD:P: |
| Nordøy 200355parallel | Mod and high risk | atorvastatin | 10 | Fish/marine oils.  | 22 | NR | Mean: Median SD: SE:Lower: Upper: | Mean:-2.8% mean: Median:SD:7.2P:<0.05 | Mean:Median:SD:P:0.92 |  | medium |
|  |  Placebo | 20 | Mean:Median SD: SE:Lower: Upper: | Mean:-3.0Median:SD:8.1P: |
| Reyes 198459parallel | Low and/or Moderate | hydrochlorothiazide | 50 | Magnesium.  | 13 | Supine diastolic | Mean: 104.4Median SD: SE:3.9Lower: Upper: | Mean:-6% mean: Median:SD:P:<0.05 | Mean:Median:SD:P: | Data for % change measured from graph and verified with numerical data in abstract | medium |
|  |  Placebo | 8 | Mean:1.5Median SD: SE:4.2Lower: Upper: | Mean:% mean: -3.4Median:SD:P:<0.05 |
| Reyes 198459parallel | Low and/or Moderate | hydrochlorothiazide | 50 | Magnesium.  | 13 | Erect diastolic blood pressure | Mean: 106Median SD: SE:2Lower: Upper: | Mean:-5% mean: Median:SD:P: | Mean:Median:SD:P: | Data extracted from bar charts - method of extraction verified for other variables that had corresponding numerical summary. In this case for final mean and SEM 1.9 cm = 40 mmHg and results rounded to nearest whole mmHg. For % change from time of randomization 1.1 cm = 2.5% and results rounded to nearest 0.5% | medium |
|  Placebo | 8 | Mean: 105Median SD: SE:4Lower: Upper: | Mean:-3% mean: Median:SD:P: |
| Dehmer 198817parallel | At high risk for CHD | aspirin + Dipyridamole + ca channel blockers) | ASA: 325; dipyridamole: 225; Ca blocker: NR | Omega-3 (EPA, DHA, or both).  | 43 | NR | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  |  No treatment (aside from CVD drug) | 39 | Mean:36Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Wolf 200668crossover | Low and/or Moderate | ASA | 500 | ginkgo biloba | NR | NR | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: | Study states that: Laboratory findings in all subjects were unremarkable and did not indicate any differences between the treatment groups. Similarly, no noteworthy changes of vital sign variables occurred during the study | low-medium |
|  |  | NR | Mean:Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Paolisso 199556crossover | At high risk for CHD | nifedipine | 88 | Vitamin E | 30 | NR | Mean: 85Median SD: SE:0.7Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | Placebo | 30 | Mean:86Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Lungershausen 199438crossover | Unclear | b-blockers | NR | Fish/marine oils | 25 | Clinical diastolic BP - Resting for 5 min, empty bladder, fasted and no exercise for 2 hours; average of 3 or 4 readings after discarding initial reading; measured using automated oscillometric monitor | Mean: 72.5Median SD: SE:Lower: Upper: | Mean:% mean: Median:SD:P: | Mean:Median:SD:P:<0.05 | Data of mean measured from histogram (10 mmHg = 2.2 cm). Measure of dispersion not stated. This study is at risk of selective outcome reporting; p-values for crude difference also don't make sense in context of graph. I would approach this data with e | medium |
|  | Placebo | 25 | Mean:75.5Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Lungershausen 199438crossover | Unclear | b-blockers | NR | Fish/marine oils | 25 | Ambulatory diastolic BP - Measured over next 24 hours using Spacelab 90207 instrument, same time of day; taken at 20 min intervals during wake and every 1 hour during sleep. | Mean: 76Median SD: SE:Lower: Upper: | Mean:2.3% mean: Median:SD:0.8P: | Mean:Median:SD:P:<0.01 | Data of mean measured from histogram (10 mmHg = 2.2 cm). Measure of dispersion not stated. Data of mean difference in text. This study is at risk of selective outcome reporting; p-values for crude difference also don't make sense in context of graph.  | medium |
|  | Placebo | 25 | Mean:78Median SD: SE:Lower: Upper: | Mean:Median:SD:1P: |
| Mueller 199151crossover | Low and/or Moderate | aspirin | 325-single dose | Fish/marine oils | 12 | before and 90 minutes after a single oral 325-mg dose of aspirin. Done by blinded operator | Mean: 77.5Median SD: 11.7SE:Lower: Upper: | Mean:-2% mean: Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | Placebo | 12 | Mean:74.08Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Maki 200841crossover | Low and/or Moderate | simvastatin | 20 | Omega-3  | 39 | At rest, seated | Mean: Median SD: SE:Lower: Upper: | Mean:% mean: -3.3Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | Placebo | 40 | Mean:Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |
| Wirell 199467Crossover | Unclear | metoprolol, atenolol, pindolol & propanolol | NR | magnesium | 39 | standing | Mean: 100.84Median SD: 9.48 | NR | Mean:Median:SD:P: |  | medium |
|  | Placebo | 39 | Mean:102.49 | NR |
| Wirell 199467Crossover | Unclear | metoprolol, atenolol, pindolol & propanolol | NR | magnesium | 39 | supine | Mean: 93.03Median SD: 9.37SE:Lower: Upper: | Mean:% mean: Median:SD:P: | NR |  | medium |
|  | Placebo | 39 | Mean:95.68 | NR |
|  |  |  | NR | NR |